Loading
companiesCompany
Triumvira Immunologics
Triumvira Immunologics is a Texas and Ontario cell-therapy company whose T-cell antigen coupler (TAC) engages the natural T-cell receptor rather than a CAR; TAC01-CLDN18.2 targets stomach and pancreatic cancers.
Also called: Triumvira Immunologics, Inc.
Overview
Triumvira Immunologics, with operations in Austin and Hamilton, Ontario, develops T-cell antigen coupler therapies in which an antigen-binding domain is coupled to the endogenous T-cell receptor complex, aiming for the potency of CAR-T with less toxicity. TAC01-HER2 was its first solid tumour programme and TAC01-CLDN18.2 targets Claudin 18.2 in gastric, gastro-oesophageal junction and pancreatic cancers in a phase 1/2 trial.
Headquarters
Austin, Texas, US
Scorecard
All companies#454of 1244 companies, score 7
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
Website
Phase 2TCR-T cell therapy
TAC01-CLDN18.2 is an experimental TCR-T cell therapy from Triumvira Immunologics in phase 2 trials, aimed at Claudin 18.2.
Similar pages
drugs
Phase 2TCR-T cell therapy